Drug
PD-L1 antibody
PD-L1 antibody is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_2
3
75%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
recruiting375%
not_yet_recruiting125%
Recent Activity
3 active trials
Showing 4 of 4
not_yet_recruitingphase_2
Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
NCT07503639
recruitingphase_2
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
NCT07472153
recruitingphase_2
PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
NCT06742424
recruitingphase_1
Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma
NCT04977167
Clinical Trials (4)
Showing 4 of 4 trials
NCT07503639Phase 2
Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
NCT07472153Phase 2
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
NCT06742424Phase 2
PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
NCT04977167Phase 1
Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4